Jakob E. Baumeister
Research Interests
Jakob E. Baumeister has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
Benjamin W. Puffer
NorthStar Medical Radioisotopes, LLC , 1800 Gateway Blvd
2 shared publicationsCory A. Hawkins
NorthStar Medical Radioisotopes, LLC , 1800 Gateway Blvd
2 shared publicationsDaniel J. De Vries
NorthStar Medical Radioisotopes, LLC , 1800 Gateway Blvd
2 shared publications- Joshua B. McCormick
NorthStar Medical Radioisotopes, LLC , 1800 Gateway Blvd
2 shared publications John W. Brown
NorthStar Medical Radioisotopes, LLC, 1800 Gateway Blvd., Beloit, Wisconsin 53511, United States
1 shared publicationMiguel Toro-GonzálEz
NorthStar Medical Radioisotopes, LLC , 1800 Gateway Blvd
1 shared publication
Latest Publications
- Open Access
- 21 October 2026
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 11 (43) , 66699-66711
Determination of 226Ra in 225Ac Active Pharmaceutical Ingredients by ICP-QQQ-MS
Growing demand for 225Ac-radiopharmaceuticals in targeted α therapy (TAT) has led to the development of new and diverse 225Ac manufacturing processes. While this has augmented global 225Ac supply, it has also created a need for common analytical methods to ensure 225Ac active pharmaceutical ingredients (APIs) meet uniform expectations for safety and efficacy. A particular challenge is the measurement of long-lived radionuclidic impurities (e.g., 227Ac, 226Ra, or 229Th). Many of the common radiometric techniques for radiopharmaceutical quality control suffer from poor sensitivity and long measurement times when applied to long-lived radionuclides. Mass spectrometry presents an attractive alternative owing to greater sensitivity for long-lived radionuclides and faster sample measurement. Several new 225Ac manufacturing processes use the long-lived radionuclide 226Ra as a starting material. This work reports a method for the determination of 226Ra in 225Ac APIs using triple quadrupole inductively coupled plasma mass spectrometry (ICP-QQQ-MS). The sensitivity and interference formation characteristics of multiple instrument modes (STD, KED, O2) were evaluated to identify the best configuration for 226Ra determination. The polyatomic ion 225Ac1H+ was identified as an interference at m/z = 226 in both STD mode and KED mode, however, the use of O2 as a reaction gas effectively removed this interference. Thus, the measurement of 226Ra at m/z = 226 → 226 in O2 reaction mode provided the best combination of sensitivity and specificity. This methodology was evaluated against appropriate criteria for accuracy, precision, specificity, linearity, and lower range limits. Accuracy and precision were evaluated by spike recovery studies using 226Ra spiked 225Ac API solutions. Spike recoveries were 85–114% for samples with 0.0500 to 0.997 ng L –1 of 226Ra. Repeatability (n = 6, one analysis) and intermediate precision (n = 12, two analyses) were evaluated by replicate determinations of 226Ra spiked samples (0.499 ng L–1) giving RSDs of 3.8% and 6.5%, respectively. The instrumental detection limit and quantitation limit were estimated to be 0.010 ng L–1 (0.36 Bq L–1) and 0.030 ng L–1 (1.1 Bq L–1), respectively. The proposed methodology allows for rapid, sensitive determination of 226Ra in 225Ac APIs. Implementation into 225Ac manufacturing processes will support high standards of product safety and efficacy.
- 21 October 2026
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 11 (43) , 66699-66711
Open AccessDetermination of 226Ra in 225Ac Active Pharmaceutical Ingredients by ICP-QQQ-MS
Growing demand for 225Ac-radiopharmaceuticals in targeted α therapy (TAT) has led to the development of new and diverse 225Ac manufacturing processes. While this has augmented global 225Ac supply, it has also created a need for common analytical methods to ensure 225Ac active pharmaceutical ingredients (APIs) meet uniform expectations for safety and efficacy. A particular challenge is the measurement of long-lived radionuclidic impurities (e.g., 227Ac, 226Ra, or 229Th). Many of the common radiometric techniques for radiopharmaceutical quality control suffer from poor sensitivity and long measurement times when applied to long-lived radionuclides. Mass spectrometry presents an attractive alternative owing to greater sensitivity for long-lived radionuclides and faster sample measurement. Several new 225Ac manufacturing processes use the long-lived radionuclide 226Ra as a starting material. This work reports a method for the determination of 226Ra in 225Ac APIs using triple quadrupole inductively coupled plasma mass spectrometry (ICP-QQQ-MS). The sensitivity and interference formation characteristics of multiple instrument modes (STD, KED, O2) were evaluated to identify the best configuration for 226Ra determination. The polyatomic ion 225Ac1H+ was identified as an interference at m/z = 226 in both STD mode and KED mode, however, the use of O2 as a reaction gas effectively removed this interference. Thus, the measurement of 226Ra at m/z = 226 → 226 in O2 reaction mode provided the best combination of sensitivity and specificity. This methodology was evaluated against appropriate criteria for accuracy, precision, specificity, linearity, and lower range limits. Accuracy and precision were evaluated by spike recovery studies using 226Ra spiked 225Ac API solutions. Spike recoveries were 85–114% for samples with 0.0500 to 0.997 ng L –1 of 226Ra. Repeatability (n = 6, one analysis) and intermediate precision (n = 12, two analyses) were evaluated by replicate determinations of 226Ra spiked samples (0.499 ng L–1) giving RSDs of 3.8% and 6.5%, respectively. The instrumental detection limit and quantitation limit were estimated to be 0.010 ng L–1 (0.36 Bq L–1) and 0.030 ng L–1 (1.1 Bq L–1), respectively. The proposed methodology allows for rapid, sensitive determination of 226Ra in 225Ac APIs. Implementation into 225Ac manufacturing processes will support high standards of product safety and efficacy.
- Open Access
- 11 November 2025
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 10 (46) , 56741-56752
Measurement of 227 Ac by Isotopic Ratio with 225 Ac Using ICP-MS
A method is reported for the measurement of 227Ac using inductively coupled plasma mass spectrometry (ICP-MS) and isotope ratio analysis. The method has application for the quality testing of 225Ac produced as an active pharmaceutical ingredient (API). The 225Ac/227Ac isotope ratio is measured directly from ICP-MS count rate data and converted to an 225Ac/227Ac activity ratio by using basic nuclear decay equations. The activity ratio, which is itself a measure of radioisotopic purity, is coupled with an orthogonal measurement of 225Ac activity to obtain an absolute 227Ac activity. Thus, the method may be used to report the 227Ac content of an 225Ac API in absolute or relative terms. The methodology was evaluated against appropriate validation criteria (e.g., linearity, accuracy, precision, specificity) by analyzing a series of solutions containing known quantities of 225Ac and 227Ac. Accuracy was evaluated using a spike recovery study. The spike recoveries were 100–108% for samples with 0.100 to 2.00 ng L–1 of 227Ac and 74–91% for 0.025 ng L–1 of 227Ac. Intermediate precision was measured as 4.1% using replicate measurements (n = 12, two instruments) of 227Ac spiked samples (0.5 ng L–1). The instrumental detection limits for 227Ac were shown to be as low as 23 Bq L–1 (0.0086 ng L–1), which is lower than comparable methods for the quantification of 227Ac in 225Ac APIs. Actinium-225 samples are analyzed under this method without any need for 225Ac decay or 227Ac daughter in-growth. Sample preparation involves simple dilution of the 225Ac API in 3% HCl/1% HNO3. The analysis takes as little as 2 h using equipment common to radioanalytical laboratories. Thus, the measurement of 227Ac by this method can be performed as part of routine 225Ac API quality testing and reported on release documents. This is a significant advantage over radiometric methods reported for the quantification of 227Ac in 225Ac APIs, which require days to weeks before reportable results can be obtained. The measurement of 227Ac by ICP-MS and isotope ratio analysis is rapid, accurate, and sensitive. The implementation of this method for 225Ac API quality testing will help 225Ac producers and end-users ensure product quality and demonstrate regulatory compliance.
- 11 November 2025
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 10 (46) , 56741-56752
Open AccessMeasurement of 227 Ac by Isotopic Ratio with 225 Ac Using ICP-MS
A method is reported for the measurement of 227Ac using inductively coupled plasma mass spectrometry (ICP-MS) and isotope ratio analysis. The method has application for the quality testing of 225Ac produced as an active pharmaceutical ingredient (API). The 225Ac/227Ac isotope ratio is measured directly from ICP-MS count rate data and converted to an 225Ac/227Ac activity ratio by using basic nuclear decay equations. The activity ratio, which is itself a measure of radioisotopic purity, is coupled with an orthogonal measurement of 225Ac activity to obtain an absolute 227Ac activity. Thus, the method may be used to report the 227Ac content of an 225Ac API in absolute or relative terms. The methodology was evaluated against appropriate validation criteria (e.g., linearity, accuracy, precision, specificity) by analyzing a series of solutions containing known quantities of 225Ac and 227Ac. Accuracy was evaluated using a spike recovery study. The spike recoveries were 100–108% for samples with 0.100 to 2.00 ng L–1 of 227Ac and 74–91% for 0.025 ng L–1 of 227Ac. Intermediate precision was measured as 4.1% using replicate measurements (n = 12, two instruments) of 227Ac spiked samples (0.5 ng L–1). The instrumental detection limits for 227Ac were shown to be as low as 23 Bq L–1 (0.0086 ng L–1), which is lower than comparable methods for the quantification of 227Ac in 225Ac APIs. Actinium-225 samples are analyzed under this method without any need for 225Ac decay or 227Ac daughter in-growth. Sample preparation involves simple dilution of the 225Ac API in 3% HCl/1% HNO3. The analysis takes as little as 2 h using equipment common to radioanalytical laboratories. Thus, the measurement of 227Ac by this method can be performed as part of routine 225Ac API quality testing and reported on release documents. This is a significant advantage over radiometric methods reported for the quantification of 227Ac in 225Ac APIs, which require days to weeks before reportable results can be obtained. The measurement of 227Ac by ICP-MS and isotope ratio analysis is rapid, accurate, and sensitive. The implementation of this method for 225Ac API quality testing will help 225Ac producers and end-users ensure product quality and demonstrate regulatory compliance.